Aurora news releases
St. Luke`s Medical Center only Milwaukee hospital to test vaccine for advanced prostate cancerThursday, April 22, 2004
MILWAUKEE, Wis, St. Luke’s Medical Center in Milwaukee is the only Milwaukee hospital conducting a clinical research trial of an experimental vaccine for prostate cancer. The vaccine, called Provenge®, is designed to trigger a patient’s own immune system to seek out and destroy cancer cells. Currently, The Immunotherapy Program and its physicians, John Hanson, M.D. and Jonathan Treisman M.D., are enrolling men in the trial. To be considered for the trial, a patient must have cancer that has spread outside the prostate (metastatic), have cancer that has progressed while on hormone therapy, have a Gleason score of 7 or lower and have no cancer-related pain.
Provenge is being studied to determine if it helps men with advanced prostate cancer fight the disease by stimulating their body’s natural defenses. It is hoped that the experimental vaccine delays progression of prostate cancer and the time to the development of disease-related pain.
“This experimental vaccine is designed to use a patient’s own cells to fight against prostate cancer, ” says Dr. Hanson. “This trial is for men who have metastatic prostate cancer, but who have limited treatments available.”
For more information on the trial please call 1-866-4-PROSTATE (1-866-477-6782) or contact the St. Luke’s Immunotherapy Program at 414-649-5818 .
St. Luke’s Medical Center is a part of Aurora Health Care, a not-for-profit Wisconsin health care provider and a nationally recognized leader in efforts to improve the quality of health care. Aurora offers services at sites in 80 communities throughout eastern Wisconsin.
Prostate Cancer Facts and Figures
(Cancer incidence and death numbers are from the 2003/2004 American Cancer Society Cancer Facts and Figures)
# # #